2023’s best medtech innovations
Category: Best Medical Technology
Nominee: Roche Elecsys Beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys Phospho-Tau (181P) CSF (p-Tau181) assays
Roche’s Elecsys cerebrospinal fluid assays can detect biomarkers of Alzheimer’s disease. [Photo courtesy of Roche]
“The abnormal phosphorylation of tau protein leads to formation of intracellular neurofibrillary tangles,” Roche says. “Together with the amyloid plaques, these modifications constitute the hallmark pathologies in [Alzheimer’s disease] and changes in these biomarkers were shown to occur before clinical symptoms.”
Roche Diagnostics said the Elecsys CSF assays support diagnosis at early disease stages, when treatment is most effective.
“Globally, up to 75% of people living with Alzheimer’s disease have not been diagnosed, and those who have often report a long and complicated process5,” Roche Diagnostics CEO Thomas Schinecker said in a news release. “The Elecsys AD CSF assays have the potential to guide more people with suspected Alzheimer’s disease towards a diagnosis than ever before. As we are starting to see exciting results for new potential Alzheimer’s treatments, reliable tests that have been clinically validated will be critical in ensuring the right patients are identified and able to benefit from them.”
